Progress in Dodecafluoropentane Emulsion as a Neuroprotective Agent in a Rabbit Stroke Model
Dodecafluoropentane emulsion (DDFPe) in 250 nm nanodroplets seems to swell modestly to accept and carry large amounts of oxygen in the body at >29 °C. Small particle size allows oxygen delivery even into hypoxic tissue unreachable by erythrocytes. Using permanent cerebral embolic occlusion in rabbits, we assessed DDFPe dose response as a neuroprotectant at 7 and 24 h post-embolization without lysis of arterial obstructions and investigated blood pharmacokinetics. New Zealand White rabbits (N = 56) received cerebral angiography and embolic spheres (diameter = 700–900 μm) occluded middle and/or anterior cerebral arteries. Intravenous DDFPe dosing (2 % w/v emulsion) began at 60 min and repeated every 90 min until sacrifice at 7 or 24 h post-embolization. Seven-hour groups: (1) control (embolized without treatment, N = 6), and DDFPe treatment: (2) 0.1 ml/kg (N = 7), (3) 0.3 ml/kg (N = 9), (4) 0.6 ml/kg (N = 8). Twenty-four-hour groups: (5) control (N = 16), and DDFPe treatment: (6) 0.1 ml/kg (N = 10). Infarcts as percent of total brain volume were determined using vital stains on brain sections. Other alert normal rabbits (N = 8) received IV doses followed by rapid arterial blood sampling and GC-MS analysis. Percent infarct volume means significantly decreased for all DDFPe-treated groups compared with controls, p = <0.004 to <0.03. Blood DDFP (gas) half-life was 1.45 ± 0.17 min with R = 0.958. Mean blood clearance was 78.5 ± 24.9 ml/min/kg (mean ± SE). Intravenous DDFPe decreases ischemic stroke infarct volumes. Blood half-life values are very short. The much longer therapeutic effect, >90 min, suggests multiple compartments. Lowest effective dose and maximum effective therapy duration are not yet defined. Rapid development is warranted.
KeywordsDodecafluoropentane emulsion Neuroprotective agent Stroke model Rabbit
This study was supported by the Hornick Fund for stroke research from UAMS.
Conflict of interest
WC Culp and RD Skinner have an application pending to the USPTC regarding the use of DDFPe in numerous medical situations.
- 1.Kochanek K, Xu J, Murphy SL, Minino AM, Kung H-C (2011) Deaths: Final data for 2009. Natl Vital Stat Rep 60(3):1–117Google Scholar
- 3.Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO, Trialists SWIFT (2012) Solitaire flow restoration device versus the Merci Retriever in patients with acute ischemic stroke (SWIFT): a randomized, parallel-group, non-inferiority trial (2012). Lancet 380(9849):1241–1249PubMedCrossRefGoogle Scholar
- 5.Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemart HG, Rodichok L, SAINT I and II Investigators (2008) NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39:1751–1758PubMedCrossRefGoogle Scholar
- 10.Culp WC, Woods SD, Brown AT, Lowery JD, Hennings LJ, Skinner RD, Borrelli MJ, Roberson PK. Three variations in rabbit angiographic stroke models. J Neurosci Meth, Epub ahead of print Nov 8 2012, doi: 10.1016/j/jneurometh.2012.10.107
- 13.The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit, 27 July 1998, CPMP/1342/98Google Scholar
- 16.Grayburn PA, Erickson JM, Excobar J, Womack L, Velasco CE (1995) Peripheral intravenous myocardial contrast echocardiography using a 2% dodecafluoropentane emulsion: identification of myocardial risk area and infarct size in the canine model of ischemia. J Am Coll Cardiol 26(5):1340–1347PubMedCrossRefGoogle Scholar
- 17.Khor SP (2012) Amendment to the pharmacokinetic analysis of clinical data from study SON-3600-1004a: NuvOx Formal Study ReportGoogle Scholar